Immunicum’s patent application regarding the cancer

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immunicum’s patent application regarding the cancer immune primer INTUVAX will be granted in Japan

Gothenburg, Sweden, 2015-11-20 10:05 CET (GLOBE NEWSWIRE) --  

Immunicum AB (publ) reported today that the Japan Patent Office (JPO), has announced that it intends to grant a patent relating to the Company's cancer immune primer, INTUVAX.

- We are pleased with the positive news from the Japan Patent Office, which will further strengthen the protection for our main product, says Jamal El-Mosleh, CEO of Immunicum.

The Japanease patent to be granted, with the titel ” Improved composition for inhibiting tumor cell proliferation ”, relates to allogeneic dendritic cells (DCs), stimulated by a specific cocktail, for use in the treatment of cancer by intratumoral injection of the DCs.

Immunicum’s vaccine cells are comprised of white blood cells from healthy blood donors, so-called allogeneic dendritic cells, which via a special activation process are developed into highly cancer immunogenic cells when injected intratumorally. The Company's unique cancer immune priming concept is based on over 30 years of research in the field of transplantation immunology and uses a new method to activate the body's own immune system to attack tumor cells.

For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum

Phone: +46 (0) 31 41 50 52 jamal.el-mosleh@immunicum.com

The company’s Certified Adviser is Redeye AB

Phone: +46 (0) 8 545 013 31. www.redeye.se

About INTUVAX

INTUVAX is a cancer immune primer, developed for the treatment of solid tumors. Its active ingredient is activated white blood cells, so called dendritic cells, derived from healthy blood donors. Intratumoral injection of these cells is expected to lead to an inflammatory response which in turn leads to tumor-specific activation of the patient's cytotoxic T lymphocytes.

     

About Immunicum AB (publ)

Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the Company's most advanced product - INTUVAX® against kidney cancer - has been initiated. The project portfolio contains an additional clinical phase I/II study in liver cancer and an upcoming clinical phase I/II-study in gastrointestinal stromal tumors (GIST).

www.immunicum.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 392

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 139

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 255

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 253

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 204

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
LaserAway Expands to 244 Clinics Over 20 Years

Updated Category News Views 203

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 200

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 281

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 166

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Developments at Metals Exploration's La India Project

Updated Category News Views 256

Promising Outcomes of La India Gold Project Metals Exploration PLC (AIM: MTL), known for its expertise in gold production, has shared encouraging initial estimates from its internal analysis concerning the La India gold project in Nicaragua. These findings highlight a notable advancement when compared to the previous Bankable Feasibility Study (BFS) undertaken by SRK...

Continue Reading
Palo Alto Networks Faces Downgrade Amid CyberArk Acquisition Risk

Updated Category News Views 369

Palo Alto Networks Faces Recent Downgrade Palo Alto Networks, Inc. (NASDAQ: PANW) experienced a significant dip in its stock value, falling over 5% recently. This decline came on the heels of concerns surrounding strategic risks associated with its acquisition of CyberArk Software Ltd. (NASDAQ: CYBR). Concerns Over Acquisition Integration The acquisition has sparked...

Continue Reading
Widescale Protests Erupt in Slovakia Over Gas Supply Politics

Updated Category News Views 193

Protests Against Slovakia's Pivot Towards Russia In recent days, thousands of demonstrators gathered in Bratislava, expressing their discontent with Prime Minister Robert Fico's policies towards Russia amid a gas dispute with Ukraine. The protests highlighted growing concerns over Slovakia's geopolitical alignments and the implications for the country's future in Europe....

Continue Reading
Engage with The Hackett Group's Q4 2024 Earnings Call Details

Updated Category News Views 204

Join The Hackett Group for an Insightful Earnings Call The Hackett Group, Inc. (NASDAQ: HCKT) is excited to announce its upcoming earnings conference call scheduled for February 18, 2025. This call follows the release of its fourth-quarter financial results for the period ending December 27, 2024, which will be made public after the market closes on that day. Conference...

Continue Reading
Tintina Mines Welcomes New Director Amid Leadership Changes

Updated Category News Views 81

Tintina Mines Announces Leadership Changes Tintina Mines Limited (TSXV: TTS) has recently undergone a leadership transition, announcing the resignation of Mr. Ricardo Landeta from his position as Director. His decision to resign is due to personal reasons, marking a significant change for the firm. Introduction of New Director In conjunction with Mr. Landeta's departure,...

Continue Reading